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syndromeAbstract Background: High-frequency oscillatory ventilation (HFOV) is one of lung protective
strategies in acute respiratory distress syndrome (ARDS). It is not recommended to be used as ini-
tial mode of ventilation. Previous studies showed conflicting results for late use of HFOV (after pro-
longed period of conventional mechanical ventilation (CMV)). This study investigated the use of
HFOV as an early therapy (after 24 h of CMV) in the management of ARDS due to burn.
Methods: 70 burned ARDS patients were ventilated by CMV during the first 24 h (Day 0). Then,
patients were randomly allocated into two equal groups (35 each):
Group 1 (G 1 or CMV): they continued on CMV.
Group 2 (G2 or HFOV): HFOV was instituted for 72 h (Days 1, 2, 3). Then, patients were shifted to
CMV on Day 4 to continue on CMV. Ventilator settings, gas exchange parameters, hemodynamics,
sedatives, vasoactive and paralytic requirements, barotraumas and hospital mortality were recorded
and compared between the two groups.
Results: In Day 0: Demographic data, ventilator settings, gas exchange parameters, and hemody-
namics showed no significant difference between both groups. Days 1, 2, 3: there was statistically
significant decrease of FiO2 and OI accompanied by an increase in PaO2, PaO2/FiO2 and PaCO2
in G2. Day 4: while both groups on CMV, G2 patients showed statistically significant decrease
in PEEP and mPaw with same gas exchange findings on Days 1, 2, 3 between two groups. During
the study period, Hypotension was observed following HFOV in G2 and was most significant in
Day 1. G2 showed statistically significant increase in barotraumas and required more midazolam,
atracurium and norepinephrine. There was no statistically significant difference in 30 days mortality
between both groups.
Conclusions: Early HFOV therapy is effective in improving oxygenation in burn patients with
ARDS, but it failed to reduce hospital mortality.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Acute respiratory distress syndrome (ARDS) is characterized
by severe deterioration in oxygenation following acute insult,
as severe inflammation causes permeability changes in the alve-
olar capillary membrane leading to fluid shifts into the alveolar
and interstitial spaces [1]. It is manifested by hypoxemia and
bilateral infiltrates on chest radiographs with normal pul-
monary capillary wedge pressures. ARDS can be classified into
mild (PaO2/FiO2 6 300 mmHg with PEEP 5 cm H2O), moder-
ate (PaO2/FiO2 6 200 mmHg with PEEP 5 cm H2O) and sev-
ere (PaO2/FiO2 6 100 mmHg with PEEP 5 cm H2O) [2].
Burn is associated with an average mortality rate of 0.8%
[3]. It may predispose to ARDS in critically ill burn patient
due to factors leading to lung injury such as smoke inhalation,
sepsis, ventilator-induced lung Injury or a systemic inflamma-
tion in response to burn [4,5]. Lung protection plan in ventilat-
ing ARDS patients is to maintain low inspiratory driving
pressures, with lower tidal volumes (4–6 ml/kg) and the use
of limited airway pressure, with the synchronized prevention
of alveolar collapse through the use of high PEEP to keep
end-expiratory pressures above the lower inflection point on
the static pressure–volume curve of the respiratory system
[6]. Conventional mechanical ventilation (CMV) may lead to
tidal hyperinflation and shear stress effect, even when it is
administered according to a ‘lung protective strategy’ that lim-
its tidal volumes and plateau pressure [7].
In spite of advances in critical care and understanding of
ARDS pathophysiology, ARDS mortality remains as high as
48% as was reported by Villar et al., [8] and 41% as was
reported by Wang et al. [9].
So, a number of ventilation modes have been recommended
like high-frequency oscillatory ventilation (HFOV) which
requires the use of a specific designed ventilator that has been
approved by Food and Drug Administration. HFOV theory is
to deliver a continuous distending mean airway pressure
(mPaw), around which oscillations of predefined amplitude
at a high frequency (usually between 3 and 15 Hz) are obtained
by using a diaphragm. These pressure oscillations result in very
small tidal volumes (1–4 ml/kg) smaller than the anatomical
dead space. Therefore, theoretically, HFOV is the ideal ‘‘lung
protective” ventilation strategy since it provides very low pres-
sure swings, thus minimizing volutrauma and atelectrauma
and maximizing alveolar recruitment [10].
Using HFOV in ARDS patients after prolonged period of
CMV has been tried by many researchers [10–19]. They used
it as a rescue therapy for patients who remained hypoxemic
and required high levels of inspired oxygen, or those who have
plateau pressures >35 cm H2O despite 4 ml/kg tidal volumes
on CMV, and the results were conflicting. Others [11–18]
demonstrated improvement of oxygenation on HFOV in
ARDS patients with increased risk of barotraumas and unfa-
vorable hemodynamics due to high airway and intrathoracic
pressure and a decreased venous return [19–21].
1.1. Aim of the study
The aim of this study was to evaluate the efficiency and com-
plications of HFOV as an early therapy (after 24 h of CMV)for a determined period (72 h) for management of ARDS in
adult burn patients without smoke inhalation injury compared
to CMV.
1.2. Outcome measures
The primary outcome included determination of hospital mor-
tality (30-day mortality) [22]. Secondary outcomes included
assessment of gas exchange parameters and adverse events
(barotraumas and unfavorable hemodynamic).
1.3. Patients and methods
The study was performed on 70 burn patients with ARDS
(PaO2/FiO2 ratio of 200 mmHg or less) who were admitted
to ICU in north zone in KSA from 2007 to 2011. Approval
of the hospital institutional review board and obtaining a writ-
ten consent from every patient or next of kin were done.
Inclusion criteria: male or female, age 18–60 years old, burn
patients with 40% TBSA burned or more.
Patients were excluded when the patient’s age was less than
18 or over 60 years and weight was less than 35 kg, asthmatic,
pregnant and the patients with smoke inhalational injury that
was diagnosed by fiber-optic bronchoscopy when suspected.
Tracheal intubation was done to all included patients in the
first 24 h from the onset of burn as was suggested by Cancio
LC [23].
In the first 24 h (Day 0), patients were ventilated by lung
protective strategy (LPS) [24] (tidal volumes 4–6 ml/kg, RR
12–22 breaths per minute, plateau airway pressure <32 cm
H2O and PEEP 10–12 cm H2O). The patients were divided
randomly using computer generated number and concealed
using sequentially numbered, sealed opaque envelope tech-
nique into two equal groups (35 patients each):
Group 1 (CMV): patients continued on CMV by LPS for
days 1, 2, 3 and 4.
Group 2 (HFOV): patients were shifted to HFOV strategy
for 72 h for days 1, 2 and 3. Then, patients were shifted to
CMV on day 4 either for weaning or to continue on LPS.
G2 Patients were assessed after 3 h on HFOV, if they could
not achieve improvement of oxygenation parameters or could
not tolerate HFOV during study period (Days 1, 2, 3) due to
severe hypoxemia, severe hypercarbia, severe barotrauma
and severe hypotension, HFOV was terminated and they were
shifted to CMV and excluded from the study.
2. Institution of HFOV
Initial patient preparation was confirmation of ET tube
patency and airway suctioning. Continuous infusion of
midazolam (0.02–0.1 mg/kg/h), atracurium (0.4–0.8 mg/kg/h),
norepinephrine (if needed: 0.05–1 lg/kg/min) and correction
of intravascular volume status were done. Any imaging (CT)
or interventions outside ICU (any operating theater proce-
dure), bronchoscopy, echocardiography, insertion of arterial
and central venous lines were performed before starting
HFOV.
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HFOV was delivered using an adult high-frequency oscillatory
ventilator (3100B, Viasys (Care Fusion), Yorba Linda, CA,
USA).
Starting HFOV settings: A protocol for the adjustment of
HFOV was used [25]:
 FiO2 was started at 1.0 and decreased to maintain an oxy-
gen saturation of 88% or more.
 Frequency of 4–6 Hz.
 Inspiratory time of 33%, may be increased to 50%.
 Bias flow of 30–40 L/min.
 A power was adjusted to obtain oscillation (wiggles) from
shoulders till the level of mid-thigh.
 Adjustment of mPaw 4–5 cm H2O higher than plateau pres-
sure for CMV settings in hemodynamic stable patients and
only 2–3 cm H2O higher in hemodynamic unstable patients.
 ET suction by closed suction system.
4. Patient care and monitoring during HFOV
 Chest wiggling should be equal on both sides of the chest
and from shoulders till mid thighs. Patients should be
sedated and relaxed.
 Daily chest X-ray for detecting overinflation or
pneumothorax.
 Daily arterial blood gases.
 keeping SPO2 > 88%.
 Hemodynamic monitoring (HR and invasive BP) and vaso-
pressor requirements were recorded. Any hypotension or
hypovolemia was properly managed.5. Weaning from HFOV
Patients were considered ready for weaning when FiO2
requirement was 60.4 with a PaO2P 60 mmHg and mPaw
had reached 20–22 cm H2O for at least 12–24 h.
 Weaning started by gradually decreasing FiO2 and then
decreasing mPaw in increments of 1–2 cmH2O to avoid lung
derecruitment. Those patients were converted to CMV (Day
4) (LPS with plateau pressure similar to that on HFOV).
Then, patients were weaned gradually from CMV.
The recorded data included patients’ demographic data, gas
exchange parameters (FiO2, PaO2, PaO2/FiO2 ratio, PaCO2,
PH, SPO2 and OI), ventilator settings while patients on
CMV (Vt, RR, plateau pressure and PEEP) and ventilator set-
tings while patients on HFOV (frequency, mean airway pres-
sure). Oxygenation Index (OI) is defined as 100  mean
airway pressure x (FiO2/PaO2).
Hemodynamic data (mean arterial blood pressure and
heart rate) were continuously monitored and MABP was
recorded hourly, and complications related to ventilation, also
sedatives, vasoactive, neuromuscular-blocking drug dosing
requirements and 30-day hospital mortality were measured
for both groups in day 0, day 1, day 2, day 3 and day 4 and
also after 3 h on HFOV in G2.6. Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (± SD), median and range when appropriate. Com-
parison of numerical variables between the study groups was
done using Student t test for independent samples. Within
group comparisons between the different time points and the
initial point were done using paired t test for paired (matched)
samples. p values less than 0.05 was considered statistically sig-
nificant. All statistical calculations were done using computer
program SPSS (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL, USA) release 15 for Microsoft Win-
dows (2006).
6.1. Power analysis
Power analysis was done on comparison of FiO2, PEEP, PaO2/
FiO2 and OI on day 4. Student’s t test for independent samples
was chosen to perform the power analysis, the a-error level was
fixed at 0.05 and the sample size was entered to be 60 partici-
pants divided equally into 2 groups. We considered that the
reported difference is representative of the true population dif-
ference but we used the higher SD of the 2 groups. The final
results are shown in the table below. Calculations were done
using PS Power and Sample Size Calculations Software, ver-
sion 3.0.11 for MS Windows (William D. Dupont and Walton
D. Vanderbilt, USA).G1 (n= 30) G2 (n= 30) Power
(%)FiO2 0.717 ± 0.0950 0.513 ± 0.1224 >99.99PEEP (cm H2O) 11.00 ± 1.083 7.23 ± 1.633 >99.99PaO2/FiO2
(mmHg)172.64 ± 30.060 266.03 ± 70.381 99OI 18.278 ± 3.2034 9.908 ± 4.6504 >99.997. Results
70 patients were submitted to the study. They were on LPS for
the first 24 h. Then, patients were randomly divided into two
groups, 35 patients each (Group 1 (CMV) and group 2
(HFOV)). Five patients were excluded from G1 because they
died within the study period. Three of them died due to respi-
ratory failure and the other 2 died because of profound
hypotension. Also, 5 patients were excluded from G2 (two
patients were shifted from HFOV to CMV after 3 h from
HFOV due to refractory hypoxemia, one patient developed
severe barotrauma and one patient developed hemodynamic
instability). 60 patients remained in the two groups, 30 patients
each (Fig. 2).
– Demographic data showed no statistically significant differ-
ence between both groups regarding age, sex and weight
(Table 1).
– As regards CMV ventilator settings: in D0, there was no
significant difference between both groups as regards PEEP
and mPaw (Table 2) (p> 0.05), and G1 patients were
Figure 1 Adult high-frequency oscillatory ventilator (3100B).
Figure 2 Comparison between the study groups in the mean FiO2 during the study period.
*Statistically significant (p< 0.05).
Table 1 Demographic data.
G1 (n= 30) G2 (n= 30)
M/f 14/16 15/15
Age (year) 46.20 ± 10.3 44.32 ± 12.4
Weight (kg) 65.8 ± 9.3 67.6 ± 8.4
Data were presented as mean ± SD.
*Statistically significant (p< 0.05).
Table 2 Ventilator settings in both groups in Day 0.
G1 (n= 30) G2 (n= 30) p Value
PEEP (cm H2O) 12.13 ± 1.613 12.40 ± 1.793 0.547
mPaw (cm H2O) 27.07 ± 2.625 28.27 ± 3.062 0.109
Data were presented as mean ± SD.
*Statistically significant (p< 0.05).
Table 3 Ventilator settings in both groups in Day 4.
G1 (n= 30) G2 (n= 30) p Value
PEEP (cm H2O) 11.00 ± 1.083 7.23 ± 1.633 0.000
*
mPaw (cm H2O) 30.73 ± 2.164 24.00 ± 4.661 0.000
*
Data were presented as mean ± SD.
* Statistically significant (p< 0.05).
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cant decrease in PEEP and mPaw in G2 than in G1 (Table 3)
(p< 0.05).
– As regards HFOV settings in G2: in D1, 2, 3: Bias flow 37
± 2 L/min. Inspiratory time 38 ± 3%. Frequency 6
± 1 Hz. mPaw 33.41 ± 2 cm H2O.
– As regards gas exchange parameters after 3 h from starting
HFOV in G2, patients showed a statistically significant
decrease of FiO2 from 0.94 ± 0.077 to 0.832 ± 0.1163
(p< 0.05), a significant increase of both PaO2 from
Figure 3 Comparison between the study groups in the mean PaO2/FiO2 (mmHg) during the study period.
*Statistically significant
(p< 0.05).
Figure 4 Comparison between the study groups in the mean OI during the study period. *Statistically significant (p< 0.05).
Figure 5 Comparison between the study groups in the mean PaO2 (mmHg) during the study period.
*Statistically significant (p< 0.05).
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PaO2/FiO2 from 111.43 ± 12.5 to 147.56 ± 28.80 mmHg
(p< 0.05).
– As regards gas exchange parameters throughout the study
period: there was no statistically significant difference
between the two groups at D0 but at D1, 2, 3 and 4, there
was a significant decrease of FiO2, OI and a significant
increase of PaO2/FiO2, PaCO2 and PaO2 (except in D2) in
G2 compared to G1 (Figs. 2–6).
– As regards MABP: patients in G2 developed hypotention
with most statistically significant difference between both
groups was found in D1 (Fig. 7).
– HR was ranging within clinically accepted levels 62–123
beats/min and from 66–127 beats/min in G1 and G2
respectively.– As regards medication requirements: G2 patients showed
statistically significant increase in doses and number of
patients who required midazolam, atracurium and nore-
pinephrine compared to G1 (Table 4).
– As regards barotraumas: pneumothorax developed in one
patient (3.3%) in G1 versus 3 patients (10%) in G2. Inter-
costal tubes were inserted and patients continued the study.
Three patients in G2 showed subcutaneous emphysema.
– PH was ranging within clinically accepted levels from 7.36
to 7.22 and from 7.34 to 7.20 in G1 and G2 respectively.
SPO2 was ranging from 89% to 96% in G1 and from
89% to 95% in G2.
– Mortality: There was no statistically significant difference
between the two groups as regards 30-day mortality. It
was 16/30 (53.33%) in G1 versus 17/30 (56.66%) in G2.
Figure 6 Comparison between the study groups in the mean PaCO2 (mmHg) during the study period.
*Statistically significant
(p< 0.05).
Figure 7 Comparison between the study groups in MABP (mmHg) during the study period. *Statistically significant (p< 0.05).
Table 4 Medication requirements during D1, 2 and 3 in both groups.
G1 (n= 30) G2 (n= 30) p value
Midazolam (mg/kg/h) 0.04 ± 0.2 0.8 ± 0.1 <0.0001*
Number of patients required/n (%) 15/30 (50%) 30/30 (100%)
Atracurium (mg/kg/h) 0.3 ± 0.03 0.6 ± 0.1 <0.0001*
Number of patients required/n (%) 8/30 (26.6%) 22/30 (73.3%)
Norepinephrine (lg/kg/min) 0.07 ± 0.03 0.4 ± 0.05 <.0001*
Number of patients required/n (%) 5/30 (16.6%) 13/30 (43.3%)
Data were presented as mean ± SD.
* Statistically significant (p< 0.05).
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The use of HFOV in ARDS and the ideal timing for its use are
still not decided. Selection of patients, timing of HFOV appli-
cation, number of days of CMV before HFOV and patient
condition before HFOV initiation may represent important
factors that determine the outcome and modify HFOV appli-
cation plan.
The present protocol considered the first 3 h on HFOV as a
cutoff time at which the patient was considered non-responder
and excluded if he didn’t show oxygenation improvement,
which was suggested by Huang et al. [29] who proved that if
there is no improvement in gas exchange within the first 3 h
on HFOV, patients should be considered to have failed HFOVand subjected to an alternative treatment as extracorporeal
support.
The current study duration was designed to be 72 h which
was supported by Camporota et al. [30] who reported that
PaO2/FiO2 improved significantly from baseline only in sur-
vivors in the first 72 h.
As regards selection of patients, identification of proper
candidates who may benefit most from HFOV is important
[29]. Also, Dries et al. [31] reported that there is no ideal respi-
ratory support strategy for the patient with inhalation injury as
pulmonary edema, bronchial edema, and secretions obstruct-
ing the airway leading to atelectasis and pneumonia. More-
over, it was concluded by Ryan et al. [32] that smoke
inhalational injury, together with age >60 years and >40%
TBSA burned, is an independent factor for mortality. So, the
present study excluded patients over 60 years and patients with
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ing foreign particles and accumulated secretions [33,34].
The main findings of this study were as follows: G2
(HFOV) patients showed significant improvement of oxygena-
tion parameters with no improvement of 30-day mortality rate,
higher PaCO2 level, higher incidence of barotraumas, higher
doses of sedatives, vasopressors and paralytic agents in com-
parison with G1 (CMV) patients.
The improvement of oxygenation parameters was denoted
by a decrease in FiO2 and OI and an increase in PaO2 (except
D2) and PaO2/FiO2 ratio in comparison with those on CMV.
This improvement was observed early and sustained for the
duration of HFOV period (days 1, 2, 3) and sustained after
shifting patients to CMV (day 4). In spite of this oxygenation
improvement, HFOV did not reduce 30-day mortality rate
which could be explained by that oxygenation improvement
does not indicate reduced lung injury or recovering from
pathology, moreover by high liability of ARDS patients to
multiple organ dysfunction syndrome (MOD) according to
Meduri et al. [35] but the authors failed to define pathophysi-
ological relationship between ARDS and MOD.
These results were comparable to Huang et al. [29] who
studied five trials and found that HFOV significantly improved
oxygenation on day one of therapy by 24%, but did not reduce
mortality risk. It is also consistent with OSCAR trial [26] that
randomized 795 patients to HFOV or CMV, and they found
no difference in rates of death between the HFOV and CMV
group.
Conversely, many studies [26,27] did not support the use of
HFOV as a salvage measure for refractory hypoxemia. More-
over, OSCILLATE trial [27] that randomized 548 patients to
either CMV or HFOV was terminated prematurely by the data
safety management committee due to higher mortality in the
HFOV group. Also, Salahuddin et al. [28] concluded that it
was not an ideal ‘rescue’ mode as it increased mortality
(72.5%) in HFOV compared to (53%) in CMV.
On the other hand, G2 patients showed higher PaCO2 level
in D1, 2, 3 than patients of G1. This is comparable to Cartotto
et al. [12] who reported that burned patients with ARDS and
smoke inhalation injury did not achieve significant improve-
ments in OI with higher rates of early HFOV failure due to
severe hypercapnia due to the difficulties in delivery of nebu-
lized medications during HFOV. The point of difference in
the current study was improvement in OI which may be
explained by exclusion of patients with smoke inhalational
injury.
As regards barotraumas, the incidence was higher in
HFOV. This incidence was less than late use of HFOV by
Mehta et al. [14] who reported the occurrence of pneumotho-
rax in 21.8% of patients who received HFOV. A similar high
percentage of patients suffered from gross barotrauma with
HFOV was reported by Ferguson et al. [38].
This low incidence was consistent with Greathouse et al.
[36], who concluded that earlier institution of HFOV improved
oxygenation and reduced rates of barotraumas in severe burn
pediatric patients and also consistent with Hodgson et al. [37]
who found the same findings in adult patients.
As regards hemodynamics, the present study showed
decrease in MABP when HFOV was started. This hemody-
namic instability was restorated by volume loading and vaso-
pressors. This was consistent with David et al. [39] who
reported that during HFOV there were decreased cardiacindex, stroke volume index, left-ventricular end-diastolic and
end systolic area indices due to higher pleural pressure. In con-
trast to Mehta et al. [15] who used HFOV in 24 ARDS patients
after varying periods of CMV, they found no significant
changes in systemic or pulmonary pressure associated with ini-
tiation and maintenance of HFOV.
In the current work, HFOV patients required higher doses
of sedatives, vasopressors and paralytic agents than those on
CMV. In consistent with the current study, Deem [40] reported
that HFOV patients needed more paralysis. In the current
study, patients showed 88% SPO2 as the lowest accepted level
as it was suggested by many authors [41–44] who reported tar-
gets of 94–98% saturation for healthy subjects and between
88% and 92% and a PaO2 > 55–60 mmHg for ARDS.
9. Conclusions
This study showed that early HFOV therapy (after 24 h of
LPS) for a determined period (72 h) can support gas exchange
and provide more effective lung recruitment than can be
achieved with conventional ventilation in burn adults with
ARDS (improved oxygenation), but increased incidence of
hypercarbia and barotraumas. HFOV failed to reduce 30-day
hospital mortality.10. Limitations of the study and problems with HFOV
HFOV needs specific training and its circuit setup causes
impaired clearance of pulmonary secretions. It also requires
heavy sedation and neuromuscular blockade which are risk
factors for intensive care-muscle weakness and required heavy
sedation that may delay weaning. The present study didn’t fol-
low up patients for long period after HFOV (only till D4) or
measure organ specific failure scores, which may explain the
high 30-day mortality in spite of oxygenation improvement.11. Recommendations
HFOV as a lung-protective ventilation strategy remains attrac-
tive, but additional clinical trials are needed to determine
whether this approach is superior to CMV.
For future studies, proper patients’ selection, determination
of the proper time for its initiation, duration and determina-
tion of optimal oscillator settings are needed to gain benefit
from using HFOV. Furthermore, Goffi [45] reported that
new monitoring technologies should be incorporated into
future HFOV for optimizing the efficacy of the machine.
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